The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...

The U.S. Food and Drug Administration (FDA) has signed off on the first-ever cream specifically approved for treating chronic ...

Adult patients with moderate to severe hand eczema with previous treatment failure or in whom topical corticosteroids are ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA.

The FDA has approved a new treatment, sold under the name Anzupgo and containing a drug called delgocitinib, as the first skin cream for adults with long-term or chronic hand eczema (CHE), which ...

Ballerup, Denmark Saturday, July 26, 2025, 15:00 Hrs [IST] ...

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

The topical JAK inhibitor is the first treatment approved specifically for adults with moderate-to-severe chronic hand eczema.

Chronic hand eczema is a common dermatological condition that presents itself as hand dermatitis which lasts over 3 months or recurs at least twice a year. 2 Genetic predispositions, ...

Delgocitinib cream significantly improved chronic hand eczema in adult patients, according to topline results from the DELTA 1 study. The phase 3 study (ClinicalTrials.gov Identifier: NCT04871711 ...